Hemostasis and malignancy

Seminars in Thrombosis and Hemostasis

Volumn 24, Issue 2, 1998, Pages 93-109

  Francis, John L ^a,b   Biggerstaff, John ^a   Amirkhosravi, Ali ^a  

^a FLORIDA HOSPITAL   (United States)

^b Walt Disney Mem Cancer Inst F   (United States)

Author keywords

Angiogenesis; Cancer; Hemostasis; Metastasis; Review; Tissue factor; Urokinase receptor

Indexed keywords

ANTIFIBRINOLYTIC AGENT; HEPARIN; THROMBOPLASTIN; UROKINASE RECEPTOR;

ANGIOGENESIS; BLOOD CLOTTING; CONFERENCE PAPER; DISSEMINATED INTRAVASCULAR CLOTTING; FIBRIN DEPOSITION; HEMOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; VASCULARIZATION;

EID: 0031894497     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-995829     Document Type: Conference Paper

References (211)

1. Trousseau A. Phlegmasia alba dolens. In: Anonymous. Clinique Medicale de l'Hotel de Paris. The New Sydenham Society, London 1865;3:94-96
2. Thompson CM, Rodgers RL. Analysis of autopsy records of 157 cases of carcinoma of the pancreas with particular reference to the incidence of thromboembolism. Am J Med Sci 1952;223:469-476
3. Dvorak HF. Thrombosis and cancer. Hum Pathol 1987;18: 275-284
4. Goldberg RJ, Seneff M, Gore JM, et al. Occult malignant neoplasm in patients with deep venous thrombosis. Arch Intern Med 1987;147:251-253
5. Bastounis EA, Karayiannakis AJ, Makri GG, Alexiou D, Papalambros EL. The incidence of occult cancer in patients with deep venous thrombosis: A prospective study. J Intern Med 1996;239:153-156
6. Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996;125:785-793
7. Prandoni P, Lensing AWA, Büller HR, et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992;327:1128-1133
8. Naschitz JE, Yeshurun D, Eldar S, Lev LM. Diagnosis of cancer-associated vascular disorders. Cancer 1996;77:1759-1767
9. Bilgrami S, Greenberg BR, Weinstein RE, Hair GA, Rickles FR. Recurrent venous thrombosis as the presenting manifestation of acute lymphocytic leukemia: Leukemic cell procoagulant activity is not responsible for the hypercoagulable state. Med Pediatr Oncol 1995;24:40-45
10. Adamson DJA, Currie JM. Occult malignancy is associated with venous thrombosis unresponsive to adequate anticoagulation. Br J Clin Pract 1993;47:190-191
11. Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajes SB, The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemostas 1995;74:1055-1058
12. Peck SD, Reiquam CW. Disseminated intravascular coagulation in cancer patients: Supportive evidence. Cancer 1973;31: 1114-1119
13. Sun NCJ, Bowie EJW, Kazmier FJ, Elveback LR, Owen CA. Blood coagulation studies in patients with cancer. Mayo Clin Proc 1974;49:636-641
14. Sun NCJ, McAfee WM, Hum GJ, Weiner JM. Hemostatic abnormalities in malignancy, a prospective study of one hundred eight patients. Part I. Coagulation studies. Am J Clin Pathol 1979;71:10-16
15. Rasche H, Dietrich M. Hemostatic abnormalities associated with malignant disease. Eur J Cancer 1977;13:1053-1064
16. Bick RL. Alterations of hemostasis associated with malignancy. Etiology, pathophysiology, diagnosis and management. Semin Thromb Hemostas 1978;5:1-26
17. Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau's syndrome revisited. Blood 1983;62: 14-31
18. Kies MS, Posch JJ, Giolama JP, Rubin RN. Hemostatic function in cancer patients. Cancer 1980;46:831-837
19. Miller SP, Sanchez-Avalos J, Stefanski T, Zuckerman L. Coagulation disorders in cancer I. Clinical and laboratory studies. Cancer 1967;20:1452-1465
20. Edwards RL, Rickles FR, Moritz TE, et al. Anormalities of blood coagulation tests in patients with cancer. Am J Clin Pathol 1987;88:596-602
21. Slichter SJ, Harker LA. Hemostasis in malignancy. Ann NY Acad Sci 1974;230:252-262
22. Davis RB, Theologides A, Kennedy BJ. Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant diseases. Ann Intern Med 1969;71: 67-80
23. Bidet JM, Ferriere JP, Besse G, Chollet P, Gaillard G, Plagne R. Evaluation of β-thromboglobulin levels in cancer patients: Effects of antitumor chemotherapy. Thromb Res 1980;19: 429-433
24. Tuszynski GP, Smith M, Rothman VL, et al. Thrombospondin levels in patients with malignancy. Thromb Haemostas 1992; 67:607-611
25. Walz DA. Thrombospondin as a mediator of cancer cell adhesion in metastasis. Cancer Metastasis Rev 1992;11:313-324
26. Boukerche H, Berthier-Vergnes O, Tabone E, Bailly M. Doré J F, McGregor JL. Thrombospondin modulates melanomaplatelet interactions and melanoma tumour cell growth in vivo. Br J Cancer 1995;72:108-116
27. Francis JL. Armstrong DJ. Acquired dysfibrinogenaemia in liver disease. J Clin Pathol 1982;35:667-672
28. Brain MC, Azzopardi JG, Baker LRI, Pineo GF, Roberts PD, Dacie JV. Microangiopathic hemolytic anaemia and mucin-forming adenocarcinoma. Br J Haematol 1970;18:183-193
29. Lyman GH, Bettigale RF, Robson E, Ambrus JL, Urban H. Fibrinogen kinetics in patients with neoplastic disease. Cancer 1978;41:1113-1122
30. Mombelli G, Roux A, Haeberli A, Staub PW. Comparison of 125T-fibrinogen kinetics and fibrinopeptide A in patients with disseminated neoplasias. Blood 1982;60:381-388
31. Rubin RN, Kies MS, Posch JJ. Measurements of antithrombin III in solid tumor patients with and without hepatic metastases. Thromb Res 1980;18:353-360
32. Taguchi O, Gabazza EC, Yoshida M, Yamakami T, Kobayashi H, Shima T. High plasma level of plasmin-α2-plasmin inhibitor complex is predictor of poor prognosis in patients with lung cancer. Clin Chim Acta 1996;244:69-81
33. Carlsson S. Fibrinogen degradation products in serum from patients with cancer. Acta Chir Scand 1973;139:499-502
34. Peuscher FW, Cleton FJ, Armstrong L, et al. Significance of plasma fibrinopeptide A (FPA) in patients with malignancy. J Lab Clin Med 1980;96:5-14
35. Myers TJ, Rickles FR, Barb C, Cronlund M. Fibrinopeptide A in acute leukemia: Relationship of activation of blood coagulation to disease activity. Blood 1981;57:518-525
36. Rickles FR, Edwards RL, Barb C, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Fibrinopeptide A generation and tumor growth. Cancer 1983;51:301-307
37. Seitz R, Rappe N, Kraus M, et al. Activation of coagulation and fibrinolysis in patients with lung cancer - relation to tumour stage and prognosis. Blood Coag Fibrinolysis 1993;4:249-254
38. Tripodi A, Mannucci PM, Chantarangkul V. et al. Markers of procoagulant imbalance in patients with localized melanomas and autoimmune disorders. Br J Haematol 1993;84:670-674
39. Duncan A, Howard T, League A. Markers of coagulation & hemostasis activation (MOCHA) as indicators of unsuspected malignancy. Thromb Haemostas 1997;Suppl:123(Abst)
40. Edwards RL, Rickles FR, Cronlund M. Abnormalities of blood coagulation in patients with cancer. Mononuclear cell tissue factor generation. J Lab Clin Invest 1981;98:917-928
41. Carvalho MG, Francis JL. Monocyte tissue factor levels in normal subjects and patients with cancer. Thromb Haemostas 1993;69:604(Abst)
42. Amirkhosravi A, Alexander M, May K, et al. The importance of platelets in the expression of monocyte tissue factor antigen measured by a new whole blood flow cytometric assay. Thromb Haemostas 1996;75:87-95
43. Spillert CR, Lazaro EJ. Shortened endotoxin-activated clotting times in patients with carcinoma. Am Surg 1987;53:164-166
44. Spillert CR, Curtis GT, Lazaro EJ. Assessment of monocyte function in breast disease. South Med J 1988;81:164-166
45. Mellor H, Taylor I, Roath OS, Francis JL. Whole blood procoagulant activity in breast and colorectal cancer. J Clin Pathol 1989;42:489-494
46. Parmar J, Taylor I, Roath OS, Francis JL. Procoagulant activity in whole blood from patients with breast and colorectal cancer. Blood Coag Fibrinolysis 1990;1:127-132
47. Koyama T, Nishida K, Ohdama S, et al. Determination of plasma tissue factor antigen and its clinical significance. Br J Haematol 1994;87:343-347
48. Francis JL, Carvalho MG, Francis DA. The clinical value of tissue factor measurements. Blood Coag Fibrinolysis 1995;6: S37-S44
49. Aoki N, von Kaulla KN. The procoagulant in human urine: Purification, assay and some biochemical and physiological properties. Thromb Diath Haemorrh 1966;16:586-605
50. Matsuda M, Aoki N. Purification and characterization of procoagulant in human urine. Thromb Res 1978;13:311-324
51. Labarrere CA, Esmon CT, Carson SD, Faulk WP. Concordant expression of tissue factor and class II MHC antigens in human placental endothelium. Placenta 1990;11:309-318
52. Carty N, Taylor I, Roath OS, El-Baruni K, Francis JL. Urinary tissue factor activity in colorectal disease. Br J Surg 1990;77: 1091-1094
53. Adamson AS, Francis JL, Roath OS, Witherow RO, Snell ME. Urinary tissue factor levels in transitional cell carcinoma of the bladder. J Urol 1992;148:449-452
54. Adamson AS, Francis JL, Witherow RO, Snell ME. Urinary tissue factor in prostatic carcinoma. A potential marker of metastatic spread? Br J Urol 1993;71:587-592
55. von Kaulla KN, Ostendorf P, von Kaulla E. The impedance machine: A new bed side coagulation recording device. J Med 1975;6:73-87
56. Francis JL, Francis DA. Gunathilagan GJ. Assessment of hypercoagulability in patients with cancer using the Sonoclot analyzer and thromboelastography. Thromb Res 1994;74: 335-346
57. Amirkhosravi A, Biggerstaff JP, Warnes G, Francis DA, Francis JL. Determination of tumor cell procoagulant activity by Sonoclot analysis in whole blood. Thromb Res 1996;84:323-332
58. Caprini JA, Zuckerman L, Cohen E, Vagher JP, Lipp V. The identification of accelerated coagulability. Thromb Res 1976; 9:167-180
59. Crissman JD. Is there clinical relevance for therapies which disrupt the metastatic cascade? In: Honn KV, Sloane BF, eds. Hemostatic Mechanisms and Metastasis. Boston: Martinus Nijhoff; 1984:1-14
60. Gastpar H. Stickiness of platelets and tumor cells influenced by drugs. Thromb Diath Haemorrh 1970;42:291(Abst)
61. Honn KV, Meyer J. Thromboxanes and prostacyclin: Positive and negative modulators of tumor growth. Biochem Biophys Res Commun 1981;102:1122-1129
62. Gastpar H, Ambrus JL, van Eimeren W. Experimental and clinical experience with pyrimido-pyrimidine derivatives in the inhibition of malignant metastasis formation. In: Honn KV, Sloane BF, eds. Hemostatic Mechanisms and Metastasis. Boston: Martinus Nijhoff; 1984:393-408
63. Honn KV, Onada JM, Pampalona K, et al. Inhibition by dihydropyridine class calcium channel blockers of tumor cell-platelet-endothelial interactions in vitro and in vivo. Biochem Pharmacol 1985;34:235-241
64. Bastida E, Escolar G, Almirall L, Ordinas A. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thromb Haemostas 1986;55:333-337
65. Orme S, Ketcham AS. The effect of prolonged anticoagulation on spontaneous metastasis. Surg Forum 1967;18:84-85
66. Fisher B, Fisher ER. Anticoagulants and tumor cell lodgment. Cancer Res 1967;27:421-425
67. Amirkhosravi M, Francis JL. Coagulation activation by MC28 fibrosarcoma cells facilitates lung tumor formation. Thromb Haemostas 1995;73:59-65
68. Hilgard P, Schulte H, Wetzig G, Schmitt G, Schmidt CG. Oral anticoagulation in the treatment of a spontaneously metastasising murine tumor (3LL). Br J Cancer 1977;35:78-85
69. Hilgard P. Experimental vitamin K deficiency and spontaneous metastases. Br J Cancer 1977;35:891-897
70. Goeting NLM, Trotter GA, Taylor I. Effect of warfarin on formation and growth of pre-neoplastic lesions in chemically-induced colorectal cancer in the rat. Br J Surg 1986;73: 487-489
71. Poggi A, Mussoni L, Kornblihtt L, Ballabio E, de Gaetano G, Donati MB. Warfarin enantiomers, anticoagulation and experimental tumour metastasis. Lancet 1978:63-164
72. Hilgard P, Maat B. Mechanism of lung tumour colony reduction caused by coumarin anticoagulalion. Eur J Cancer 1979;15: 183-187
73. Amirkhosravi M, Francis JL. Role of procoagulant activity in lung seeding of MC28 fibrosarcoma cells. Thromb Haemostas 1993;69:602(Abst)
74. Thornes RD. Anticoagulant therapy in patients with cancer. J Irish Med Assoc 1969;62:426(Abst)
75. Thornes RD. Fibrin and cancer. Br Med J 1972;1:110-111
76. Chlebowski RT, Gota CH, Chan KK, Weiner JM, Block JB, Baternan JR. Clinical and pharmacokinetic effects of combined warfarin and 5-fluorouracil in advanced colon cancer. Cancer Res 1982;42:4827-4830
77. Zacharski LR, Henderson WG, Rickles FR, et al. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon head and neck, and prostate. Final report of VA cooperative study #75. Cancer 1984;53:2046-2052
78. Maurer LH, Herndon JE, Hollis DR, et al. A randomized trial of chemotherapy (ct) and radiation therapy (rt) with or without warfarin (w) for limited disease (ld) small cell lung cancer (sclc) - calgb 8534. Proc Ann Meet Am Soc Clin Oncol 1993;12:A1119(Abst)
79. Carpi A, Sagripanti A, Poddighe R, Gherarducci G, Nicolini A. Cancer incidence and mortality in patients with heart disease. Effect of oral anticoagulant therapy. Am J Clin Oncol 1995; 18:15-18
80. Kiricuta I, Todorutiu C, Muresian T, Risca R. Prophylaxis of metastases formation by unspecific immunologic stimulation associated with heparintherapy. Cancer 1973;31:1392-1396
81. Eichbaum FW. Anticoagulants and cancer, a review. Rev Bras Pesqui Med Biol 1975;8:489-496 8
82. Walz DA, Fenton JW. The role of thrombin in tumor cell metastasis. Invasion Metastasis 1994;14:303-3 08
83. Gasic GJ. Thrombin inhibitors promote metastasis. Period Biol 1991;93:633-640
84. Antachopoulos CT, Iliopoulos DC, Gagos S, et al. In vitro eff fects of heparin on SW480 tumor cell-matrix interaction. Anticancer Res 1995;15:1411-1416
85. Folkman J, Langer R, Linhardt RJ, Haudenschild C, Taylor S. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221:719-725
86. Lebeau B, Chastang C, Brechot JM, et al.Subcutaneous heparin treatment increases survival in small cell lung cancer. "Petites cellules" group. Cancer 1994;74:38-45
87. Kingston RD, Fielding JW, Palmer MK. Perioperative heparin: A possible adjuvant to surgery in colo-rectal cancer? Int J Colorectal Dis 1993;8:111-115
88. Giraldi T, Kopitar M, Sava G. Antimetastatic effects of a leukocyte intracellular inhibitor of neutral proteases. Cancer Res 1977;37:3834-3835
89. Turner GA, Weiss L. Analysis of aprotinin-induced enhancement of metastasis of Lewis lung tumors in mice. Cancer Res 1981;41:2576-2580
90. Bailey IS, Loizidou M, Hind R, Francis JL. The effect of aprotinin on metastatic tumour cell implantation and growth. Thromb Haemostas 1991;65:105(Abst)
91. Markus G. The role of hemostasis and fibrinolysis in the metastatic spread of cancer. Semin Thromb Hemostas 1984; 10:61-70
92. Cliffton EE, Agostino D. Factors affecting the development of metastatic cancer. Cancer 1962:15:276-283
93. Tanaka N, Ogawa M, Tanaka K, Kinjo M, Kohga S. Effects of tranexamic acid and urokinase on hematogenous metastases of Lewis lung carcinoma in mice. Invasion Metastasis 1981;1:149-157
94. Tanaka N, Ogawa H, Kinjo M, Kohga S, Tanaka K. Ultrastructural study of the effects of tranexamic acid and urokinase on metastasis of Lewis lung carcinoma. Br J Cancer 1982;46: 428-435
95. O'Meara RAQ. Coagulative properties of cancers. Irish Med J 1958;394:474-479
96. Day DW. The adenoma-carcinoma sequence. Scand J Gastroenterol 1984;19(suppl 104):99-107
97. Dvorak HF, Senger DR, Dvorak AM. Fibrin as a component of the tumour stroma: Origins and biological significance. Cancer Metast Rev 1983;2:41-73
98. Dvorak HF. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986;315:1650-1659
99. Dvorak HF, Orenstein NS, Carvalho AC, et al. Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J Immunol 1979;122:166-174
100. Dvorak HF, Dickerson GR, Dvorak AM, Manseau EJ, Pyne K. Human breast carcinoma: Fibrin deposits and desmoplasia. Inflammatory cell type and distribution. Microvasculature and infarction. J Natl Cancer Inst 1981;67:335-345
101. Colvin IF, Johnson RA, Mihm MC, Dvorak HF. Role of the clotting system in cell-mediated hypersensitivity. J Exp Med 1973;138:686-697
102. Dvorak HF, Galli SJ, Dvorak AM. Expression of cell-mediated hypersensitivity in vivo - recent advances. Int Rev Exp Pathol 1980;32:119-194
103. Peters RF, Jasani MK, Tweed MF, Knight I, Lane DA. Extravas-cular fibrin formation and fibrinolysis in a model of intlam-rnalion accompanying cellular hypersensilivily. In: Lane DA. Henschen A, Jasani MK, eds. Fibrinogen-Fibrin Formation and Fibrinolysis. Berlin: Walter de Gruyter: 1986:337-345
104. Talbot MD, Peters RF, Tweed MF, Jasani MK. Extravascular fibrin deposition in cellular hypersensitivity - the role of T-lymphocyte-macrophage interactions. In: Lane DA, Henschen A, Jasani MK, eds. Fibrinogen-Fibrin Formation and Fibrinolysis. Berlin: Walter de Gruyter: 1986:347-355
105. Biggerstaff JP, Amirkhosravi A, Francis JL. Three-dimensional visualization and quantitation of fibrin in solid tumors by confocal laser scanning microscopy. Cytometry 1997;29: 122-127
106. McKinna JA, Rowbotham HD. Experimental studies of factors causing blood borne dissemination in cancer of the colon and rectum. Proc Roy Soc Med 1971;64:569-570
107. Wood S. Pathogenesis of metastasis formation observed in vivo in the rabbit ear chamber. Arch Pathol 1958;66:550-568
108. Warren BA. The microinjury hypothesis and metastasis. In: Honn KV, Sloane BF, eds. Hemostatic Mechanisms and Metastasis. Boston: Martinus Nijhoff; 1984:56-61
109. Edwards RL, Rickles FR. Macrophage procoagulants. Prog Haemostas Thromb 1984;7:183-209
110. Zacharski LR, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornstein DL. Clotting factors in tumour tissue: Implications for cancer therapy. Blood Coag Fibrinolysis 1990;1:71-78
111. Dvorak HF, Senger DR, Dvorak AM, Harvey VS, McDonagh J. Regulation of extravascular coagulation by microvascular permeability. Science 1985;227:1059-1062
112. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA 1968; 61:46-52
113. Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S. Platelet-tumor cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer 1973;11:704-718
114. Hara Y, Steiner M, Baldini MG. Characterisation of the platelet-aggregating activity of tumor cells. Cancer Res 1980;40: 1217-1222
115. Gasic GJ, Gasic TB, Stewart GJ. Mechanisms of platelet aggregation by murine tumor cell spheroids. In: Honn KV, Sloane BF (eds.). Hemostatic mechanisms and metastasis. Martinus Nijhoff Publishing, Boston 1984:127-138
116. Ferroni P, Lenti L, Guadagni F, et al. Possible involvement of tumour cell membrane gangliosides in platelet-tumour cell interactions. Eur J Cancer [A] 1995;31A:79-84
117. Grignani G, Pacchiarini L, Ricetti MM, et al. Mechanisms of platelet activation by cultured human cancer cells and cells freshly isolated from tumor tissues. Invasion Metastasis 1989;9:298-309
118. Radomski MW, Jenkins DC, Holmes L, Moncada S. Human colorectal adenocarcinoma cells - differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 1991;51:6073-6078
119. Oleksowicz L, Mrowiec Z, Schwartz E, Khorshidi M, Dutcher JP, Puszkin E. Characterization of tumor-induced platelet aggregation: The role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells. Thromb Res 1995;79:261-274
120. Nierodzik ML, Bain RM, Liu LX, Shivji M, Takeshita K, Karpatkin S. Presence of the seven transmembrane thrombin receptor on human tumour cells: Effect of activation on tumour adhesion to platelets and tumor tyrosine phosphorylation. Br J Haematol 1996;92:452-457
121. Sakuragawa N, Takahashi K, Hoshiyama M, et al. The extract from the tissue of gastric cancer as procoagulant in disseminated intravascular coagulation syndrome. Thromb Res 1977; 10:457-463
122. Mussoni L, Conforti G, Gambacorti-Passerini C, et al. Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture. Eur J Cancer Clin Oncol 1986:22:373-380
123. Zacharski LR, Memoli VA, Rousseau SM. Coagulation-cancer interaction in situ in renal cell carcinoma. Blood 1986;68: 394-399
124. Dvorak HF, van de Water L, Bitzer AM, et al. Procoagulant activity associated with plasma membrane vesicles shed by cultured tumor cells. Cancer Res 1983;43:4334-4342
125. Cajot J, Kruithof EKO, Scheunling W, Sordat B, Bachmann F. Plasminogen activators, plasminogen activator inhibitors and procoagulant analysed in twenty human tumor cell lines. Int J Cancer 1986;38:719-727
126. Zacharski LR, Dunwiddle C, Nutt EM, Hunt J, Memoli VA. Cellular localization of activated factor X by Xa-specific probes. Thromb Haemostas 1991;65:545-548
127. Muszbek L, Adany R, Szegedi G, Polgar J, Kavai M. Factor XIII of blood coagulation in human monocytes. Thromb Res 1985;37:401-410
128. Altieri DC, Mannucci PM, Capitanio AM. Binding of fibrinogen to human monocytes. J Clin Invest 1986;78:968-976
129. Gordon SG, Franks JJ, Lewis B. Cancer procoagulant: A factor X-activating procoagulant from malignant tissue. Thromb Res 1975;6:127-137
130. Gordon SG, Cross BA. A factor X-activating cysteine protease from malignant tissue. J Clin Invest 1981;67:1665-1671
131. Curatolo L, Colucci M, Cambini AL, et al. Evidence that cells from experimental tumours can activate coagulation factor X. Br J Cancer 1979;40:228-233
132. Colucci M, Curatolo L, Donati MB, Semeraro N. Cancer cell procoagulant: Evaluation by an amidolytic assay. Thromb Res 1980;18:589-595
133. Gilbert LC, Gordon SG. Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma cells. Cancer Res 1983;43:536-540
134. Gordon SG, Franks JJ, Lewis BJ. Comparison of procoagulant activities in extracts of normal and malignant human tissue. J Natl Cancer Inst 1979;62:773-776
135. Gordon SG, Lewis BJ. Comparison of procoagulant activity in tissue culture medium from normal and transformed fibroblasts. Cancer Res 1978;38:2467-2472
136. Dover R, Goeting NLM, Taylor I, Roath OS, Francis JL. Factor X-activating activity in patients with colorectal carcinoma. Br J Surg 1987;74:1122-1124
137. Francis JL, El-Baruni K, Roath OS, Taylor I. Factor X-activating activity in normal and malignant colorectal tissue. Thromb Res 1988;52:207-217
138. Donati MB, Gambacorti-Passerini C, Casali B, et al. Cancer procoagulant in human tumor cells: Evidence from melanoma patients. Cancer Res 1986;46:6471-6474
139. Goeting NLM, Francis JL. Blood coagulation, fibrinolysis and cancer. In: Francis JL, ed. Fibrinogen, Fibrin Stabilization and Fibrinolysis. Chichester: Ellis Horwood; 1988:372-397
140. Fasco MJ, Wilson AC, Lincoln D, Gierthy J. Evidence for a warfarin-sensitive serum factor that participates in factor X activation by Lewis lung tumor cells. Int J Cancer 1987; 39:631-637
141. Shands JW. Macrophage factor X activator formation: Metabolic requirements for synthesis of components. Blood 1985;65:169-175
142. Pusey ML, Meade TJ. Studies on the procoagulant activity of human amniotic fluid 1. Stability and coagulation factor requirements. Thromb Res 1985;39:355-368
143. Pusey ML, Meade TJ. Studies on the procoagulant activity of human amniotic fluid 2. The role of factor VII. Thromb Res 1985;39:571-585
144. Gordon SG, Hasiba U, Cross BA, Poole MA, Falanga A. Cysteine proteinase procoagulant from amnion-chorion. Blood 1985;66:1261-1265
145. Idell S, Gonzales K, Bradford H, et al. Procoagulant activity in bronchoalveolar lavage in the adult respiratory distress syndrome. Contribution of tissue factor associated with factor VII. Am Rev Resp Dis 1987;136:1466-1474
146. Zacharski LR, Memoli VA, Rousseau SM, Kisiel W. Occurrence of blood coagulation factors in small cell carcinoma of the lung. Cancer 1987;60:2675-2681
147. Zucchella M, Pacchiarini L, Tacconi F, Saporiti A, Grignani G. Different expression of procoagulant activity in human cancer-cells cultured in vitro or in cells isolated from human tumor tissues. Thromb Haemostas 1993;69:335-338
148. Poggi A, Colucci M, Delaini F, Semeraro N, Donati MB. Reduced procoagulant activity of Lewis lung carcinoma cells from mice treated with warfarin. Eur J Cancer 1980;16: 1641-1642
149. Delaini F, Colucci M, de Bellis Vitti G, et al. Cancer cell procoagulant: A novel vitamin K-dependent activity. Thromb Res 1981;24:263-266
150. Amirkhosravi M, Francis JL. Procoagulant effects of the MC28 fibrosarcoma cell line in vitro and in vivo. Br J Haematol 1993;85:736-744
151. Zacharski LR, Rosenstein R, Phillips PG. Concanavalin A inhibition of tissue factor (thromboplastin) activity. Blood 1974; 44:783-787
152. Bromberg ME, Konigsberg WH, Madison JF, Pawashe A, Garen A. Tissue factor promotes melanoma metastasis by a pathway independent of blood coagulation. Proc Natl Acad Sci USA 1995;92:8205-8209
153. Nierodzik ML, Plotkin A, Kajumo F, Karpatkin S. Thrombin stimulates tumor-platelet adhesion in vitro and metastasis in vivo. J Clin Invest 1991;87:229-236
154. Klepfish A, Greco MA, Karpatkin S. Thrombin stimulates melanoma tumor-cell binding to endothelial cells and subendothelial matrix. Int J Cancer 1993;53:978-982
155. Fischer EG, Ruf W, Mueller BM. Tissue factor-initiated thrombin generation activates the signaling thrombin receptor on malignant melanoma cells. Cancer Res 1995;55:1629-1632
156. Zacharski LR, Memoli VA, Costantini V, Wojtukiewicz MZ, Ornstein DL. Clotting factors in tumour tissue: Implications for cancer therapy. Blood Coag Fibrinolysis 1990;1:71-78
157. Szczepanski M, Lucer C, Zawadski J, Tolloczko T. Procoagulant and fibrinolytic activities of gastric and colorectal cancer. Int J Cancer 1982;30:329-333
158. Corasanti JG, Celik C, Camiolo SM, et al. Plasminogen activator content of human colon tumors and normal mucosae: Separation of enzymes and partial purification. J Natl Cancer Inst 1980;65:345-351
159. Astedt B, Holmberg L. Immunological identity of urokinase and ovarian carcinoma plasminogen activator released in tissue culture. Nature 1976;261:595-597
160. Barlow GH, Firestone SL, Robbins KC. Identification of the plasminogen activator(s) produced by the transformed liver cell line SK-HEP-1. Thromb Res 1983;32:29-34
161. Hayashi S, Yamada K. Urokinase-type plasminogen activator in ascites obtained from the patient with mammary cancer. Thromb Res 1985;38:459-467
162. Sim P, Stephens R, Fayle DRH, Doe WF. Urokinase-type plasminogen activator expression in inflammatory bowel disease tissue - quantitation of pro- and active enzyme levels. Gastroenterology 1986;90:1634(Abst)
163. Gelister JSK, Ishaq S, Mahmoud M, Gaffney PJ, Boulos PB. Tissue plasminogen activator and urokinase in human colorectal cancer. Br J Cancer 1986;54:150(Abst)
164. de Bruin PAF, Griffioen G, Verspaget HW, Verheijen JH, Lamers CBHW. Plasminogen activators and tumor development in the human colon: Activity levels in normal mucosa. adenomatous polyps and adenocarcinomas. Cancer Res 1987;47:4654-4657
165. Layer G, Burnand KG, Gaffney PJ, et al. Tissue plasminogen activators in breast cancer. Thromb Res 1987;45:601-607
166. Duffy MJ, O'Grady P. Devaney D, O'Siorain L, Fennelly JJ, Lijnen HJ. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Cancer 1988;62:531-533
167. Jänicke F, Schmitt M, Hafter R, et al. Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 1990;4:69-78
168. Foekens JA, Schmitt M, Vanputten WLJ, et al. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 1992;52:6101-6105
169. Schmitt M, Jänicke F, Moniwa N, Chucholowski N, Pache L, Graeff H. Tumor-associated urokinase-type plasminogen activator - biological and clinical significance. Biol Chem Hoppe-Seyler 1992;373:611-622
170. Del Vecchio S, Stoppelli MP, Carriero MV, et al. Human urokinase receptor concentration in malignant and benign breast tumors by in vitro quantitative autoradiography: Comparison with urokinasc levels. Cancer Res 1993;53:3198-3206
171. Bianchi E, Cohen RL, Thor AT, et al. The urokinase receptor is expressed in invasive breast cancer hut not in normal breast tissue. Cancer Res 1994;54:861-866
172. Xing RH, Rabbani SA. Overexpression of urokinase receptor in breast cancer cells results in increased tumor invasion, growth and metastasis. Int J Cancer 1996;67:423-429
173. Duggan C, Maguire T, Mcdermott E, O'Higgins N, Fennelly JJ, Duffy MJ. Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int J Cancer 1995;61:597-600
174. Fockens JA, Schmitt M, van Putten WL, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 1994;12:1648-1658
175. Bini A, Ozzello L, Di Nardo P, et al. Fibrin deposition in Lewis lung carcinoma (311) in mice transgenic for human plasminogen activator inhibitor-1 (PAI-1). FASEB J 1994;8: A669(Abst)
176. Klijn JG. Grondahl-Hansen J, Schmitt M, et al. The predictive value of the urokinase system with respect to response to tamoxifen therapy in recurrent breast cancer. Proc Ann Meet Am Soc Clin Oncol 1995;14:A72(Abst)
177. Goldfarb RH, Liotta L. Proteolytic enzymes in cancer invasion and metastasis. Semin Thromb Hemostas 1986;12:294-307
178. Goldfarb RH, Ziche M, Murano G, Liotta LA. Plasminogen activators (urokinase) mediate neovascularisation: Possible role in tumor angiogenesis. Semin Thromb Hemostas 1986;12: 337-338
179. Schultz RM, Yu H. Zhang JY. The role of urokinase and urokinase inhibitor in tumour cell metastasis. Fibrinolysis 1992;6: 23-29
180. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8
181. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-1887
182. Fontanini G, Bigini D, Vignati S, et al. Microvessel count predicts metastatic disease and survival in non-small cell lung cancer. J Pathol 1995;177:57-63
183. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: Relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-1612
184. Maeda K, Chung Y, Takatsuka S, et al. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol 1995;13:477-481
185. Weidner N, Folkman J, Pozza F, et al. Diagnostic and therapeutic applications of angiogenesis research. C R Acad Sci III 1993;316:909-918
186. Battegay EJ. Angiogenesis: Mechanistic insights, neovascular diseases, and therapeutic prospects. J Molec Med 1995;73: 333-346
187. D'Amore PA, Shim DT. Tumor angiogenesis: A physiological process or genetically determined? Cancer Metast Rev 1996; 15:205-212
188. Ambrus JL, Ambrus CM, Forgach P, et al. Studies on tumor induced angiogenesis. EXS 1992;61:436-444
189. Hansell P, Maione TE, Borgström P. Selective binding of platelet factor 4 to regions of active angiogenesis in vivo. Am J Physiol Heart Cire Physiol 1995;269:H829-H836
190. Roberts DD. Regulation of tumor growth and metastasis by thrombospondin-1. FASEB J 1996;10:1183-1191
191. Dvorak HF, Harvey VS, Estrella P, Brown LF, McDonagh J, Dvorak AM. Fibrin containing gels induce angiogenesis. Implications for tumor stroma generation and wound healing. Lab Invest 1987;57:673-686
192. Thompson WD, Stirk CM, Melvin WT, Smith EB. Plasmin, fibrin degradation and angiogenesis. Nature Med 1996;2:493
193. Zhang Y, Deng Y, Luther T, et al. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest 1994;94:1320-1327
194. Contrino J, Hair G, Kreutzer DL, Rickles FR. In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Med 1996;2:209-215
195. Tuszynski GP, Nicosia RF. The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays 1996;18:71-76
196. Bromberg ME, Garen A, Konigsberg WH. Tissue factor expression represses mRNA levels of thrombospondin-1 in melanoma cells by a pathway independent of blood coagulation. Blood 1996;88:470a(Abst)
197. Volpert OV, Stellmach V, Bouck N. The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Res Treat 1995;36:119-126
198. Mattern J, Koomägi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73:931-934
199. Shweioki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-845
200. Shoji M, Abe K, Nawroth PP, Rickles FR. Molecular mechanisms linking thrombosis and angiogenesis in cancer. Trends Cardiovasc Med 1997;7:52-59
201. Sueishi K, Yasunaga C, Murata T, Kumamoto M, Nakagawa K, Kono S. Endothelial function in thrombosis and thrombolysis. Jpn Circ J 1992;56:192-198
202. Min HY, Doyle LV, Vitt CR, et al. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 1996;56:2428-2433
203. Alonso DF, Farías EF, Ladeda V, Davel L, Puricelli L, Joffé EBD. Effects of synthetic urokinase inhibitors on local invasion and metastasis in a murine mammary tumor model. Breast Cancer Res Treat 1996;40:209-223
204. Craft PS, Harris AL. Clinical prognostic significance of tumour angiogenesis. Ann Oncol 1994;5:305-311
205. Hildenbrand R, Dilger I, Hörlin A, Stutte HJ. Urokinase and macrophages in tumour angiogenesis. Br J Cancer 1995; 72:818-823
206. Pepper MS, Ferrara N, Orci L, Montesano R. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181: 902-906
207. Niedbala MJ, Stein M. Tumor necrosis factor induction of urokinase-type plasminogen activator in human endothelial cells. Biomed Biochim Acta 1991;50:427-436
208. Ishida T, Sugio K, Yokoyama H, et al. Overexpression of urokinase-type plasminogen activator in human lung adenocarcinoma stimulated by transforming growth factor-alpha and epidermal growth factor. Cancer J 1991;4:382-387
209. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;9:315-328
210. Eschwège V, Seddiki S, Robert A. The tissue thromboplastin inhibition test in the detection of lupus anticoagulants: Importance of a correction factor eliminating the influence of fibrinogen level. Thromb Haemostas 1996;76:65-68
211. Gately S, Twardowski P, Stack MS, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res 1996;56:4887-4890